Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue 11, 2002, Pages 1187-1192

  Basu, Kumar K ^a   Bale, Robert ^a   West, Kevin P ^a   De Caestecker, John S ^a,b  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Barrett's oesophagus; Gastro oesophageal reflux; Proton pump inhibitors

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CALCULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; INTESTINE EPITHELIUM; MALE; MANOMETRY; PH MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; STOMACH PH; SYMPTOM;

ADULT; AGED; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; COHORT STUDIES; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MANOMETRY; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; RECURRENCE;

EID: 0036865694     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200211000-00005     Document Type: Article

References (43)

1. Vaezi MF, Singh S, Richter JE. Role of acid and duodenogastric reflux in esophageal mucosal injury: A review of animal and human studies. Gastroenterology 1995; 108:1897-1907.
2. Skinner DB. The incidence of cancer in Barrett's esophagus varies according to series. In: Guili R, McCallum RW, editors. Benign lesions of the esophagus and cancer: Answer to 210 questions. New York: Springer-Verlag; 1989. pp. 764-765.
3. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Eng J Med 1985; 74:857-859.
4. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988; 75:760-763.
5. Williamson WA, Ellis FH, Gibb SP, et al. Barrett's esophagus: Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991; 151:2212-2216.
6. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's: An overated risk? Gastroenterology 1984; 87:927-933.
7. Tytgat GN, Hameeteman W. The neoplastic potential of columnar-lined (Barrett's) esophagus. World J Surg 1992; 16:308-312.
8. Cooper BT, Neuman CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg od for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12:893-897.
9. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40mg daily: Results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999; 13:1205-1209.
10. Sampliner RE. Effect of up to 3 years of high-dose lanzoprazole on Barrett's esophagus. Am J Gastroenterol 1994; 89:1844-1848.
11. Malesci A, Sauarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44:700-705.
12. Peters FTM, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: A randomised double blind study. Gut 1999; 45:489-494.
13. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93:763-767.
14. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12:1231-1234.
15. Byrne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett's esophagus by argon plasma coagulation. Am J Gastroenterol 1998; 93:1810-1815.
16. Van Laethem J-L Cremer M, Peny MO, Delhaye M, Deviere J. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: Immediate and mid-term results. Gut 1998; 43:747-751.
17. Barham CP, Jones RL, Biddlestone LR, Hardwick RH, Shepherd NA, Barr H. Photothermal laser ablation of Barrett's oesophagus: Endoscopic and histological evidence of squamous re-epithelialisation. Gut 1997; 41:281-284.
18. Berenson MM, Johnson TD, Markowitz NB, Buchi KN, Samowitz WS. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology 1993; 104:1686-1691.
19. Skinner DB, Bruno WC, Riddel RH, Schmidt H, lascone C, DeMeester TR. Barrett's esophagus: Comparison of benign and malignant cases. Ann Surg 1983; 198:554-565.
20. McClave SA, Boyce HW, Gottfried MR. Early diagnosis of columnar-lined esophagus: A new endoscopic criterion. Gastrointest Endosc 1987; 33:413-416.
21. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 1996; 110:614-621.
22. Hendel J, Hendel L, Hage E, Hendel J, Aggestrup S, Nielsen OH. Monitoring of omeprazole treatment in gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1996; 8:417-420.
23. Dodds WJ, Hogan WJ, Stef JJ, Miller WN, Lydon SB, Arndorfer RC. A rapid pull-through technique for measuring lower esophageal sphincter pressure. Gastroenterology 1975; 68:437-443.
24. Fox JE, Vidins EI, Beck IT. Observer variation in esophageal pressure assessment. Gastroenterology 1973; 65:884-888.
25. Ask P, Tibbling L. Effect of time interval between swallows on esophageal peristalsis. Am J Physiol 1980; 238:485-490.
26. Richter JE, Wu WC, Johns DN, et al. Esophageal manometry in 95 healthy adult volunteers: Variability of pressures with age and frequency of 'abnormal' contractions, Dig Dis Sci 1987; 32:583-592.
27. Fuchs KH, Demeester TR, Albertucci M. Specificity and sensitivity of objective diagnosis of gastroesophageal reflux disease. Surgery 1987; 102:575-579.
28. Johnsson F, Joelsson B, Isberg PE. Ambulatory 24 hour intraesophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. Gut 1987; 28:1145-1150.
29. Castell DO. Omeprazole works best when used properly. Eur J Gastroenterol Hepatol 1996; 8:413-414.
30. Klauser AG, Heinrich C, Schindlbeck NE, et al. Is long-term oesophageal pH monitoring of clinical value? Am J Gastroenterol 1989; 84:362-366.
31. Champion G, Richter RE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107:747-754.
32. Sharma P, Sampliner RE, Camargo E, Normalisation of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92:582-585.
33. Fass R, Sampliner RE, Malagon IB, Hayden CW, Camargo L, Wendel CS, Garewal HS. Failure of oesophageal acid control in candidates for Barretts oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14:597-602.
34. Kuo B, Castell DO. Optimal dosing of omeprazole 40mg daily: Effects on gastric acid and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91:1532-1538.
35. Klinkenberg-Knol EC, Meuwissen SGM. Combined gastric and oesophageal 24 hour pH-monitoring and oesophageal manometry in patients with reflux disease resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990; 4:485-495.
36. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998; 115:1335-1339.
37. Salminen DE, Tuominen JA, Rano OJ, Farkkila MA, Salo JA. Oesophageal acid exposure: Higher in Barrett's oesophagus than reflux oesophagitis. Ann Med 1999; 31:46-50.
38. Richter JE. Pathophysiological basis of therapy for gastroesophageal reflux disease. Dis Esophagus 1994; 7:223-229.
39. Niemantsverdriet EC, Timmer R, Breumelhof R, Smout AJPM. The roles of excessive gastro-oesophageal reflux, disordered oesophageal motility and decreased mucosal sensitivity in the pathogenesis of Barrett's oesophagus. Eur J Gastroenterol Hepatol 1997; 9:515-519.
40. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89:989-991.
41. Ouatu-Lascar R, Triadafilapoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraoesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93:711-716.
42. Ortiz A, Martinez de Haro LF, Parrilla P, Molina J, Bermejo J, Munitiz V. 24 Hour pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors. Br J Surg 1996; 83:274-278.
43. Fackler WK, Ours TM, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625-632.